The Development and Characterization of Two Monoclonal Antibodies Against the Conjugates and Derivatives of the Immunometabolite Itaconate
We have developed two monoclonal antibodies, CPTC-2MeSC-1 and CPTC-2MeSC-2, against itaconate and its conjugates with sulfhydryl-containing biomolecules such as cysteines. Itaconate is a dicarboxylic acid metabolite that has recently gained much interest for its anti-inflammatory properties in many biological models. We have synthesized an itaconate-cysteine conjugate ITA-Cys designed to mimic in vivo Michael adducts of itaconate. Two monoclonal antibodies against ITA-Cys, CPTC-2MeSC-1 and CPTC-2MeSC, were developed and shown to have high immunoreactivity to unconjugated itaconate, itaconate-BSA conjugates, and Michael adducts of dimethyl itaconate. We found that CPTC-2MeSC-1 and CPTC-2MeSC-2 are specific and do not bind to other structurally similar cysteine Michael adducts, including those obtained from "sister" metabolites (fumarate, cis-aconitate), itaconate isomers (citraconate), and some itaconate esters. CPTC-2MeSC-2 is a useful tool in both studying biological actions of itaconate and developing therapeutic applications of itaconate and its derivatives.
Authors
- Simona Colantonio
- Joshua J. Reading
- Tessa W. Caceres
- Sandra S. Garcia-Buntley
- Lauren Switala (ORCID: https://orcid.org/0000-0002-8121-2181)
- Lin Di (ORCID: https://orcid.org/0000-0001-6123-0422)
- Andrei Maiseyeu (ORCID: https://orcid.org/0000-0001-8830-1809)
- Bindu Lakshman
Institutions
- Frederick National Laboratory for Cancer Research (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- ACS Omega
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1021/acsomega.4c08552
- Citations
- 2
- Primary Topic
- Macrophage Migration Inhibitory Factor
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- National Heart, Lung, and Blood Institute
- National Cancer Institute
- National Institute of Environmental Health Sciences